Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1233339-22-4

Post Buying Request

1233339-22-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1233339-22-4 Usage

Description

AZ20, also known as 1233339-22-4, is a potent and highly selective inhibitor of Ataxia telangiectasia mutated and RAD3-related (ATR) kinase. It has demonstrated in vivo antitumor activity and is characterized by its ability to inhibit ATR kinase with an IC50 of 5 nM in vitro and 50 nM in HT29 colorectal adenocarcinoma cells.

Uses

Used in Anticancer Applications:
AZ20 is used as an antitumor agent for its potent and selective inhibition of ATR kinase, which plays a crucial role in DNA damage response and cell cycle regulation. This selective inhibition has shown in vivo antitumor activity, making AZ20 a promising candidate for cancer treatment.
Used in Combination Therapy:
AZ20 is used in combination therapy with gemcitabine for synergistic inhibition of tumor cell growth and initiation of cell death in pancreatic cancer cell lines. This combination therapy enhances the efficacy of gemcitabine and may improve treatment outcomes for pancreatic cancer patients.
Used in Pharmaceutical Research:
AZ20 is used as a research tool for studying the role of ATR kinase in various cellular processes, including DNA damage response and cell cycle regulation. Its potent and selective inhibition of ATR kinase makes it a valuable compound for investigating the molecular mechanisms underlying cancer development and progression, as well as for identifying potential therapeutic targets for cancer treatment.

References

1) Foote?et al.?(2013)?Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy In Vivo Antitumor Activity; J. Med. Chem.?56?2125 2) Liu?et al.?(2017)?Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cell lines through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine; Oncol. Rep.?37?3377

Check Digit Verification of cas no

The CAS Registry Mumber 1233339-22-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,3,3,3 and 9 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1233339-22:
(9*1)+(8*2)+(7*3)+(6*3)+(5*3)+(4*3)+(3*9)+(2*2)+(1*2)=124
124 % 10 = 4
So 1233339-22-4 is a valid CAS Registry Number.

1233339-22-4 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma

  • (SML1328)  AZ20  ≥98% (HPLC)

  • 1233339-22-4

  • SML1328-5MG

  • 2,103.66CNY

  • Detail
  • Sigma

  • (SML1328)  AZ20  ≥98% (HPLC)

  • 1233339-22-4

  • SML1328-25MG

  • 8,453.25CNY

  • Detail

1233339-22-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name (3R)-4-[2-(3H-indol-4-yl)-6-(1-methylsulfonylcyclopropyl)pyrimidin-4-yl]-3-methylmorpholine

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1233339-22-4 SDS

1233339-22-4Downstream Products

1233339-22-4Relevant articles and documents

Efficient Syntheses of Diverse, Medicinally Relevant Targets Planned by Computer and Executed in the Laboratory

Klucznik, Tomasz,Mikulak-Klucznik, Barbara,McCormack, Michael P.,Lima, Heather,Szymku?, Sara,Bhowmick, Manishabrata,Molga, Karol,Zhou, Yubai,Rickershauser, Lindsey,Gajewska, Ewa P.,Toutchkine, Alexei,Dittwald, Piotr,Startek, Micha? P.,Kirkovits, Gregory J.,Roszak, Rafa?,Adamski, Ariel,Sieredzińska, Bianka,Mrksich, Milan,Trice, Sarah L.J.,Grzybowski, Bartosz A.

supporting information, p. 522 - 532 (2018/03/21)

The Chematica program was used to autonomously design synthetic pathways to eight structurally diverse targets, including seven commercially valuable bioactive substances and one natural product. All of these computer-planned routes were successfully executed in the laboratory and offer significant yield improvements and cost savings over previous approaches, provide alternatives to patented routes, or produce targets that were not synthesized previously. Although computers have demonstrated the ability to challenge humans in various games of strategy, their use in the automated planning of organic syntheses remains unprecedented. As a result of the impact that such a tool could have on the synthetic community, the past half century has seen numerous attempts to create in silico chemical intelligence. However, there has not been a successful demonstration of a synthetic route designed by machine and then executed in the laboratory. Here, we describe an experiment where the software program Chematica designed syntheses leading to eight commercially valuable and/or medicinally relevant targets; in each case tested, Chematica significantly improved on previous approaches or identified efficient routes to targets for which previous synthetic attempts had failed. These results indicate that now and in the future, chemists can finally benefit from having an “in silico colleague” that constantly learns, never forgets, and will never retire. Multistep synthetic routes to eight structurally diverse and medicinally relevant targets were planned autonomously by the Chematica computer program, which combines expert chemical knowledge with network-search and artificial-intelligence algorithms. All of the proposed syntheses were successfully executed in the laboratory and offer substantial yield improvements and cost savings over previous approaches or provide the first documented route to a given target. These results provide the long-awaited validation of a computer program in practically relevant synthetic design.

PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER

-

Page/Page column 68-69, (2010/07/09)

There is provided pyrimidinyl indole compounds of Formula (I), or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly for treating cancer.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1233339-22-4